CD8A and colon carcinoma: We report for the first-time αTIGIT in combination with bintrafusp alfa results in prominent antitumor activity and increase in overall survival in both the MC38-CEA colon carcinoma and the TC1, HPV+ lung carcinoma models, which are dependent on CD4+ and CD8+ T cells.